Knowledge of High Skin Cancer Risk Might Modify Risky Behaviors
People with a high risk of skin cancer accurately assessed risk and reported lower likelihood of future tanning bed use.
Melanoma
Risk of Leptomeningeal Metastasis in Melanoma Linked to Anatomic, Surgical Factors
Researchers found that entry into the ventricle space during surgical resection elevated the risk of leptomeningeal disease in patients with melanoma brain metastases.
No Added Benefit With Spartalizumab in BRAF-Mutant Melanoma
Progression-free survival outcomes were similar with and without spartalizumab.
Kimmtrak Approved for Unresectable or Metastatic Uveal Melanoma
The approval was based on data from a phase 2 trial.
Giving Immune Checkpoint Inhibitors Within 90 Days of Radiation Appears Safe
Rates of adverse events were generally similar between patients who did and did not receive radiation.
Chemotherapy ‘Has Limited Role’ After ICI Failure in Metastatic Melanoma
The objective response rate was 12.5%, and the median progression-free survival was 2.6 months.
Relatlimab-Nivolumab Ups PFS in Untreated Advanced Melanoma
The median progression-free survival was 10.1 months with relatlimab-nivolumab and 4.6 months with nivolumab.
High-Fiber Diet May Benefit Melanoma Patients on Immunotherapy
Higher intake of dietary fiber was linked to longer progression-free survival in melanoma patients on immune checkpoint blockade.
HLA Variant May Predict Poor Outcomes of Immunotherapy in Cancer Patients
HLA-A*03 was associated with worse progression-free and overall survival.
Many Oncology Drugs Approved for Genomic Indications Not Studied for Overall Survival Outcomes
Overall survival data were available for about half of the drugs.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...